Back to blog home
Video Spotlight:
Kevin gives an overview of the exclusive license and collaboration agreement Bicycle has entered with Ionis to develop targeted oligonucleotide therapeutics.
Want To Stay Connected?
Stay up to date with the team and learn how we are working to help patients waiting for new treatments. Follow us on Twitter, connect with us on LinkedIn.
